GSK’s Acquisition of RAPT Therapeutics Nears Completion
Published on 02/22/2026 at 16:29 | Redaktion boerse-global.de
The planned acquisition of RAPT Therapeutics by pharmaceutical giant GSK is entering its final stages. As the deal progresses toward a conclusion, investor focus is shifting to key deadlines and the potential of the company’s immunology-focused drug pipeline.
A pivotal date in this process is March 2, 2026, which marks the expiration of the tender offer period. GSK has stated its intention to finalize the acquisition within the first quarter of this year, assuming all customary closing conditions are satisfied.
This transaction is undergoing standard legal reviews by shareholder law firms. These routine examinations, common for deals of this scale, assess the fairness of the transaction’s structure to the Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
